Please select a video from the list below.
Selexipag for the Treatment of Connective Tissue Disease-Associated PAH
This program reviews the recent publication by Gaine et al (Eur Respir J, 2017) regarding use of the novel prostacyclin receptor agonist, selexipag, in patients with connective tissue disease related pulmonary hypertension. This review, by paper co-author Dr. Richard Channick examines the essential efficacy and safety of this drug in a group of patients considered hard-to-treat.
Recent Video
Most Viewed
Specialties :                    Search :
RESPITE Study Results
RESPITE Study Results Views - 785
ICU Management of PH
ICU Management of PH Views - 124
Animal Models of PH
Animal Models of PH Views - 64
Holding Court in PAH
Holding Court in PAH Views - 1597
 CTEPH Basics
CTEPH Basics Views - 71
The INFORM Study
The INFORM Study Views - 401